Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease

by Vandana Singh, Benzinga Editor

June 2, 2021 9:41 AM | 1 min read |

The FDA has granted Orphan Drug Designation to Soleno Therapeutics Inc SLNO DCCR (diazoxide choline) Extended-Release tablets for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease.
Von Gierke disease is a condition in which the body cannot break down glycogen. Glycogen is a form of sugar (glucose) that is stored in the liver and muscles.
DCCR previously received Orphan Drug Designation for the treatment of Prader-Willi syndrome.
Orphan Drug Designation qualifies a candidate for various development incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval.
Price Action: SLNO shares are up 29.9% at $1.33 during the market session on the last check Wednesday.